Navigation Links
Helix BioPharma reports Q2 2008 highlights, financial results
Date:3/10/2008

------------------

25,967 14,273

------------------

------------------

-------------------------------------------------------------------------

The Company's unaudited interim Consolidated Statements of Operations and Cash Flows for the three and six month periods ended January 31, 2008 and 2007 are summarized below:

-------------------------------------------------------------------------

Consolidated Statements of Operations

for the three and six month periods ended January 31, 2008 and 2007

(thousand $, except for per share data)

Three months Six months

ended January 31 ended January 31

2008 2007 2008 2007

--------------------------------------

Revenue:

Product revenue 652 757 1,406 1,453

License fees and royalties 139 135 270 265

Research and development

contracts - - - -

--------------------------------------

791 892 1,676 1,718

Expenses:

Cost of sales 269 310 582 600

Research and development 1,029 1,065 1,811 1,973

Operating, general and admin 1,245 1,578 2,558 2,447

Amortization of capital assets 63 73 129 150

Amortization of intangible assets 3 39 10 79

Stock-based compensation
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
2. Helix BioPharma Chairman resigns
3. Helix BioPharma Corp. announces fiscal 2007 results
4. Helix BioPharma Corp. announces management changes
5. Helix BioPharma announces $16.9 million private placement of common shares
6. Helix BioPharma announces Q1 2008 financial results
7. Helix BioPharma closes $16.9 million private placement of common shares
8. Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format
9. Helix BioPharma shareholders vote in favour of management
10. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
11. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 2015 Ascendis Pharma A/S (Nasdaq: ... innovative TransCon technology to address significant unmet medical ... six-month Phase 2 study to evaluate the safety ... 53 treatment-naïve, pre-pubertal children with growth hormone deficiency, ... with the top-line results from our Phase 2 ...
(Date:7/30/2015)... ... July 30, 2015 , ... As part of its 2015 growth plan and as a follow ... service business units, Whitehouse Laboratories is pleased to announce that it has begun construction ... Center of Excellence and will be strictly dedicated to basic USP 51, USP 61, and ...
(Date:7/29/2015)... -- Sanofi, un leader mondial et ... le premier semestre 2015. Le Directeur Général ... Visionner l,interview vidéo et lire la transcription :  ... sommaire de l,interview :  - Résultats ... - Diabète - Praluent ...
(Date:7/29/2015)... +14% CER / 20% of sales) led the regional performance in the second ... well as solid contributions from Korea, India and ... East / Africa (Q2 2015: +3% CER ... Turkey and the United Kingdom . The ... HPV sales, on demand across all customer classes. The top seven emerging markets ...
Breaking Biology Technology:Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7Whitehouse Labs Formally Announces Plans to Open a Microbiological Laboratory 2QIAGEN Reports Results for Second Quarter and First Half of 2015 2QIAGEN Reports Results for Second Quarter and First Half of 2015 3QIAGEN Reports Results for Second Quarter and First Half of 2015 4QIAGEN Reports Results for Second Quarter and First Half of 2015 5QIAGEN Reports Results for Second Quarter and First Half of 2015 6QIAGEN Reports Results for Second Quarter and First Half of 2015 7QIAGEN Reports Results for Second Quarter and First Half of 2015 8QIAGEN Reports Results for Second Quarter and First Half of 2015 9QIAGEN Reports Results for Second Quarter and First Half of 2015 10
... ... that have $1 - $20 million in yearly revenues and have experienced significant growth over ... , ... September 24, 2009 -- Orange County has become a hub for innovation and growth and ...
... NEW YORK, Sept. 24 Reportlinker.com announces that a new market ... World Market for Cancer Therapeutics and Biotherapeutics, 3rd. ... http://www.reportlinker.com/p0119229/World-Market-for-Cancer-Therapeutics-and-Biotherapeutics-3rd-Edition-The.html , , ... year. This number is expected to increase by 2.4% by 2020 ...
... , , WAYNE, ... Bonatti, M.D., Professor of Surgery and Director of Coronary Surgery ... Center in Baltimore, has completed the world,s first use of ... robotic and fully endoscopic heart surgery. The new cardiopulmonary bypass ...
Cached Biology Technology:Southern California Venture Network to Recognize Local Companies At 2009 Emerging Growth Awards 2Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The Report 2Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The Report 3Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The Report 4Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The Report 5Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The Report 6Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The Report 7Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The Report 8Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The Report 9Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The Report 10Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The Report 11MAQUET Cardiovascular Announces Leading Robotic Heart Surgeon Performs First Beating Heart Fully Endoscopic Bypass Surgery Using Miniaturized Cardiopulmonary Bypass System 2MAQUET Cardiovascular Announces Leading Robotic Heart Surgeon Performs First Beating Heart Fully Endoscopic Bypass Surgery Using Miniaturized Cardiopulmonary Bypass System 3MAQUET Cardiovascular Announces Leading Robotic Heart Surgeon Performs First Beating Heart Fully Endoscopic Bypass Surgery Using Miniaturized Cardiopulmonary Bypass System 4
(Date:7/23/2015)... BEDFORD, Mass., July 23, 2015 Aware, Inc. (NASDAQ: ... services, today reported financial results for its second quarter ended ... quarter of 2015 was $4.5 million, a decrease of 33% ...  Net income in the second quarter of 2015 was $0.3 ... million, or $0.04 per diluted share, in the same period ...
(Date:7/21/2015)... 21, 2015  NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market ... that it has filed provisional patent 62/192218 for ... This invention highlights next generation payment ... account, but also the user using unique personal ...
(Date:7/13/2015)... Calif. , July 13, 2015 ... developer of human interface solutions, today announced sampling ... touch and display driver integration (TDDI) product targeting ... the first to combine Synaptics , best-in-class ... proven display driver technology developed in the company,s ...
Breaking Biology News(10 mins):Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3
... in French . , Prof. Claudio Cuello at ... can emulate Alzheimer,s disease in humans, enabling research that will ... brain condition leading to a progressive decline of memory and ... in the past, rats are more intelligent than other rodents ...
... This release is available in <A HREF=",http://chinese.eurekalert.org/zh/pub_releases/2010-03/sfeb-ftc032910.php,">Chinese ... known antiepileptic agent widely used throughout the world. ... have suggested that, as for other anticonvulsant drugs ... including valproate and carbamazepine, phenytoin may have mood-stabilizing ...
... Helmholtz Zentrum Mnchen has launched a new cooperative project ... therapeutic approaches against lymphoid tumors. With a two-year grant ... two partners will seek to further develop lentiviral vector ... cancer form and to devise approaches for treatment. ...
Cached Biology News:From the clinics to the bench and back -- phenytoin as a mood stabilizer? 2Development of new anti-cancer gene therapy approach using lentiviral vectors 2
Without sodium bicarbonate. Sterile, Cell culture tested...
... a fluorescence scanner with 1 or 2 ... Protein, CGH, ) spotted on standard slides ... InnoScan700 scanners include three different models:, ... simultaneous dual fluorescence scanner (635nm and 532nm). ...
... Open Frame DNAscope is an integrated confocal ... and readily integrated into your specific application. ... we can tailor the system to your ... optical scanning design has been modularized and ...
... Hybridization chambers with forced convection Temperature range ... to 99.9 C / 212 F Patented ... results DS controller Timer 0 to ... accuracy of a tenth of a degree ...
Biology Products: